High early death rate in elderly patients with acute promyelocytic leukemia treated with all-trans retinoic acid combined chemotherapy
- 229 Downloads
In a recent article in Cancer Science, Ono et al.  reported that elderly patients (60–70 years) with acute promyelocytic leukemia (APL) showed a higher induction death rate and non-relapse mortality during consolidation therapy, resulting in a significantly inferior overall survival rate. Many APL clinical trials have found that intensive chemotherapy combined with all-trans retinoic acid (ATRA) dramatically improved patient outcomes. Therefore, it has been generally thought that even elderly APL patients should be treated aggressively to increase the likelihood of curing the disease. However, most clinical trials have excluded elderly patients. Indeed, the German Acute Myeloid Leukemia Cooperative Group showed that 30 % of their newly diagnosed APL patients were age ≥60 years, and of these, 25 % were ineligible for the therapeutic study due to death before therapy, reduced performance status, comorbidity, or concomitant malignancy . Moreover, elderly patients show...
KeywordsAcute Myeloid Leukemia Acute Promyelocytic Leukemia Arsenic Trioxide Consolidation Therapy Gemtuzumab Ozogamicin
Conflict of interest
The authors have no conflict of interest.